figitumumab + docetaxel + prednisone

This is an investigational **combination regimen** consisting of three drugs: figitumumab, docetaxel, and prednisone. - **Figitumumab** is a fully human IgG2 monoclonal antibody that targets and inhibits the insulin-like growth factor 1 receptor (IGF-1R), blocking a signaling pathway involved in tumor cell proliferation and survival. - **Docetaxel** is a microtubule inhibitor (a taxane-class chemotherapeutic) used primarily for the treatment of several cancers and works by preventing cell division through stabilization of microtubules. - **Prednisone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressant effects, also frequently used in cancer therapy regimens to reduce side effects and modulate the immune response. This regimen was explored in the context of **advanced solid tumors** (primarily advanced or castration-resistant prostate cancer and possibly non-small cell lung cancer) in early-phase clinical trials. Evidence from related studies shows that combination therapies containing figitumumab were investigated for their potential to enhance anticancer activity, but development was discontinued due to a lack of added efficacy and increased toxicity, particularly in non-small cell lung cancer[2][4][6].